Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780291 | 1.00 | FFAR1 (0.39) | FFAR1FFAR4PPARDPPARAPPARG | |
| SCHEMBL5633249 | 0.90 | PPARD (0.35) | FFAR1FFAR4PPARDPPARAPPARG | |
| SCHEMBL5633252 | 0.90 | PPARD (0.35) | FFAR1FFAR4PPARDPPARAPPARG | |
| SCHEMBL7799735 | 0.80 | KIF11 (0.38) | FFAR1 | |
| SCHEMBL7799739 | 0.80 | KIF11 (0.38) | FFAR1 | |
| SCHEMBL5480351 | 0.80 | APP (0.44) | FFAR1PPARDPPARAPPARGAPP | |
| SCHEMBL5483934 | 0.80 | APP (0.44) | FFAR1PPARDPPARAPPARGAPP | |
| SCHEMBL5480347 | 0.80 | APP (0.44) | FFAR1PPARDPPARAPPARGAPP | |
| SCHEMBL5634095 | 0.74 | PPARD (0.40) | FFAR1FFAR4PPARDPPARAPPARG | |
| SCHEMBL5634092 | 0.74 | PPARD (0.40) | FFAR1FFAR4PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| EP-0900217-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0900217-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0888355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997040042-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | FFAR1 2321/4885FFAR4 2840/4885PPARD 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.